Table 1.
Baseline characteristics of the subjects by routes and types of COVID-19 vaccines in first and second dose.
| Routes and types of vaccines | |||||||
|---|---|---|---|---|---|---|---|
| First dose - Second dose |
All | ID CoronaVac - ID ChAdOx1 |
ID ChAdOx1 - ID ChAdOx1 |
ID BNT162b2 - ID BNT162b2 |
IM ChAdOx1 - ID ChAdOx1 |
IM BNT162b2 - ID BNT162b2 |
P-value |
| Number of subjects (%) | 80 (100.0) |
20 (25.0) |
20 (25.0) |
20 (25.0) |
10 (12.5) |
10 (12.5) |
|
| Age (years); Median (IQR) | 34.5 (24.5, 44.0) |
36.5 (26.0, 45.5) |
35.0 (24.0, 41.5) |
32.5 (24.5, 42.5) |
36.5 (24.0, 48.0) |
29.5 (27.0, 36.0) |
0.928 |
| Male; n (%) | 41 (51.5) |
10 (50.0) |
12 (60.0) |
13 (65.0) |
3 (30.0) |
3 (30.0) |
0.218 |
| Body mass index (BMI: kg/m2); Median (IQR) | 23.0 (20.4, 37.1) |
25.8 (20.3, 28.4) |
23.2 (20.9, 26.1) |
21.3 (18.6, 26.0) |
23.5 (22.5, 26.2) |
21.6 (20.6, 22.6) |
0.655 |
| Underweight (< 18.50 kg/m2); n (%) |
9 (11.2) |
2 (10.0) |
1 (5.0) |
5 (25.0) |
1 (10.0) |
0 (0.0) |
0.117 |
| Normal weight (18.50 - 24.90 kg/m2); n (%) |
44 (55.0) |
7 (35.0) |
14 (70.0) |
9 (45.0) |
6 (60.0) |
8 (80.0) |
|
| Overweight and obesity (> 24.90 kg/m2); n (%) |
27 (33.7) |
11 (55.0) |
5 (25.0) |
6 (30.0) |
3 (30.0) |
2 (20.0) |
|